newsTepotinib, an investigational therapy for patients with metastatic non-small cell…
11 September 2019 | By Rachael Harper (European Pharmaceutical Review)
Tepotinib, an investigational therapy for patients with metastatic non-small cell lung cancer has been given Breakthrough Therapy Designation.